Sanofi's eczema drug is four-time blockbuster
Sanofi drug Dupixent, which Leo Pharma hopes to challenge with its tralokinumab treatment, has surpassed USD 4bn in sales.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The resurgence of the coronavirus in many countries has not put a damper on the growth of Sanofi's eczema drug Dupixent.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
